Brad Ringeisen, PhD
Brad Ringeisen, PhD is Executive Director of the Innovative Genomics Institute (IGI). Dr. Ringeisen spent four years at Defense Advanced Research Projects Agency (DARPA), most recently in the role of Director of the Biological Technologies Office where he managed a division working at the cutting edges of biology, physical sciences and engineering. Dr. Ringeisen’s office overlapped with IGI on several occasions, on the Safe Genes program, which works to develop safe and more precise genome editing tools while preventing misuse of the technology, as well as IGI’s research into innovative solutions to mitigate acute radiation sickness.
Prior to his role at DARPA, Dr. Ringeisen was the head of the Bioenergy and Biofabrication Section at the U.S. Naval Research Laboratory and spent two years developing point-of-care diagnostics for the Defense Threat Reduction Agency.
In addition to his deep leadership experience, Dr. Ringeisen is a physical chemist with a Ph.D. from the University of Wisconsin-Madison and a pioneer in the field of live cell printing.